专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012018687A1 COVALENT DIABODIES AND USES THEREOF 审中-公开
标题翻译：同性双胞胎及其用途
公开(公告)号：WO2012018687A1
公开(公告)日：2012-02-09
申请号：PCT/US2011/045922
申请日：2011-07-29
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling , RAINEY, Godfrey Jonah Anderson
发明人： JOHNSON, Leslie, S. , HUANG, Ling , RAINEY, Godfrey Jonah Anderson
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： A61K39/39558 , A61K38/164 , C07K14/315 , C07K16/2803 , C07K16/2809 , C07K16/283 , C07K16/2851 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/31 , C07K2319/70
摘要： Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.
摘要翻译：公开了抗体分子及其用于治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）的用途。双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。另外，抗原可以来自相同或不同的分子。双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如位于每个多肽链内的半胱氨酸残基的二硫键。双抗体分子可以进一步包含Fc区，其允许抗体样功能被改造成分子。

2. 发明申请

WO2009151717A3 BCR-COMPLEX-SPECIFIC ANTIBODIES AND METHODS OF USING SAME 审中-公开
标题翻译： BCR复合特异性抗体及其使用方法
公开(公告)号：WO2009151717A3
公开(公告)日：2010-05-20
申请号：PCT/US2009038171
申请日：2009-03-25
申请人： MACROGENICS INC , JOHNSON LESLIE S , HUANG LING
发明人： JOHNSON LESLIE S , HUANG LING
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及特异性结合BCR复合物的嵌合和人源化抗体，特别是涉及BCR复合物的嵌合和人源化抗体。本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

3. 发明申请

WO2009151717A2 BCR-COMPLEX-SPECIFIC ANTIBODIES AND METHODS OF USING SAME 审中-公开
标题翻译： BCR复合特异性抗体及其使用方法
公开(公告)号：WO2009151717A2
公开(公告)日：2009-12-17
申请号：PCT/US2009/038171
申请日：2009-03-25
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling
发明人： JOHNSON, Leslie, S. , HUANG, Ling
IPC分类号： A61K39/395
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及特异性结合BCR复合物的嵌合和人源化抗体，特别是涉及BCR复合物的嵌合和人源化抗体。本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

4. 发明申请

WO2007009065A3 METHODS OF TREATING AUTOIMMUNE DISEASE USING HUMANIZED ANTI-CD16A ANTIBODIES 审中-公开
标题翻译：使用人类抗CD16A抗体治疗自身免疫疾病的方法
公开(公告)号：WO2007009065A3
公开(公告)日：2009-06-04
申请号：PCT/US2006027387
申请日：2006-07-11
申请人： MACROGENICS INC , TUAILLON NADINE , JOHNSON LESLIE S , BONVINI EZIO , STEIN KATHRYN E
发明人： TUAILLON NADINE , JOHNSON LESLIE S , BONVINI EZIO , STEIN KATHRYN E
IPC分类号： C07K16/00 , A61K39/395 , C07K1/00 , C12P21/08
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/76
摘要： CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.
摘要翻译：描述了可用于减少有害免疫反应的CD16A结合蛋白。一方面，任选缺乏效应子功能的人源化抗CD16A抗体用于治疗免疫疾病，例如特发性血小板减少性紫癜和自身免疫性溶血性贫血。

5. 发明申请

WO2007147090A3 METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2007147090A3
公开(公告)日：2008-10-16
申请号：PCT/US2007071275
申请日：2007-06-14
申请人： MACROGENICS INC , KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S , PILLEMER STANLEY
发明人： KOENIG SCOTT , WILDER RONALD , BONVINI EZIO , JOHNSON LESLIE S , PILLEMER STANLEY
IPC分类号： A61K39/395 , A61K39/21 , A61K39/40
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供治疗，预防，减缓T细胞介导的免疫疾病，特别是自身免疫疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖型糖尿病（IDDM））的症状的进展或改善的方法，以及多发性硬化）通过使用抗人CD3抗体。本发明的本发明的抗体优选用于低剂量给药方案，慢性给药方案或方案，其涉及在一段时间后再次进行。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。此外，本发明的方法提供使用经修饰的抗人CD3抗体，使得与未修饰的抗人CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

6. 发明申请

WO2008019199A2 FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：WO2008019199A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/072153
申请日：2007-06-26
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , HUANG, Ling , GERENA, Robyn
发明人： JOHNSON, Leslie, S. , HUANG, Ling , GERENA, Robyn
IPC分类号： A61K39/395
CPC分类号： C07K16/283 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
摘要翻译：本发明涉及以比所述抗体或其片段结合FcγRIIA，特别是人FcγRIIA更高的亲和力特异性结合FcγRIIB，特别是人FcγRIIB的抗体或其片段。本发明还提供了抗-FcγRIIB抗体或其抗原结合片段作为用于治疗，预防，控制或改善癌症，优选B细胞恶性肿瘤，特别是B 细胞慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫病症，炎性病症，IgE介导的变应性病症或其一种或多种症状。本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。本发明还提供了通过施用本发明的抗体来增强疫苗组合物功效的方法。

7. 发明申请

WO2007147090A2 METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2007147090A2
公开(公告)日：2007-12-21
申请号：PCT/US2007/071275
申请日：2007-06-14
申请人： MACROGENICS, INC. , KOENIG, Scott , WILDER, Ronald , BONVINI, Ezio , JOHNSON, Leslie, S. , PILLEMER, Stanley
发明人： KOENIG, Scott , WILDER, Ronald , BONVINI, Ezio , JOHNSON, Leslie, S. , PILLEMER, Stanley
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供治疗，预防，减缓T细胞介导的免疫疾病，特别是自身免疫疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖性糖尿病（IDDM））的症状的进展或改善的方法，以及多发性硬化）通过使用抗人CD3抗体。本发明的本发明的抗体优选用于低剂量给药方案，慢性给药方案或方案，其涉及经过一段时间后的再次给药。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。此外，本发明的方法提供使用经修饰的抗人CD3抗体，使得与未修饰的抗人CD3抗体相比，它们表现出降低或消除的效应子功能和T细胞活化。

8. 发明申请

WO2007009064A2 METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的免疫抑制性单克隆抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2007009064A2
公开(公告)日：2007-01-18
申请号：PCT/US2006/027386
申请日：2006-07-11
申请人： MACROGENICS, INC. , KOENIG, Scott , WILDER, Ronald , BONVINI, Ezio , JOHNSON, Leslie, S.
发明人： KOENIG, Scott , WILDER, Ronald , BONVINI, Ezio , JOHNSON, Leslie, S.
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C07K16/2809 , A61K38/28 , A61K2039/505 , C07K2317/24 , C07K2317/524 , C07K2317/53 , C07K2317/71 , A61K2300/00
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non- modified anti-CD3 antibodies.
摘要翻译：本发明提供了通过使用抗CD3抗体来治疗，预防或改善T细胞介导的免疫疾病，特别是自身免疫性疾病的症状的方法。特别地，本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。另外，本发明提供抗CD3抗体的修饰，使得它们与非修饰抗CD3抗体相比表现出降低或消除的效应子功能和T细胞活化。

9. 发明申请

WO2004062619A3 SOLUBLE Fc?R FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
标题翻译：可溶性FcγR融合蛋白及其使用方法
公开(公告)号：WO2004062619A3
公开(公告)日：2006-09-14
申请号：PCT/US2004000725
申请日：2004-01-13
申请人： MACROGENICS INC , JOHNSON LESLIE S , LI HUA , TUAILLON NADINE
发明人： JOHNSON LESLIE S , LI HUA , TUAILLON NADINE
IPC分类号： A61K6/00 , A61K20060101 , A61K38/17 , A61K39/395 , A61P37/00 , C07K14/735 , C07K16/28 , C07K19/00 , C12N15/12 , C12N15/13 , C12N15/62 , C12P21/02 , C12P21/08
CPC分类号： C07K16/283 , A61K39/39541 , A61K2039/505 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2319/30 , C07K2319/32 , A61K2300/00
摘要： The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an Fc?R, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.
摘要翻译：本发明涉及分子，优选可溶性（即不是膜结合的）多肽，最优选包含FcγR的细胞外可溶性区域，其衍生物和类似物以及编码它们的核酸的可溶性融合多肽。本发明的分子特别可用于治疗，治疗或预防或改善自身免疫疾病的一种或多种症状，特别是用于改善与免疫性血小板减少性紫癜相关的血小板缺乏症。本发明提供了通过施用本发明的分子来增强用于自身免疫疾病的标准，当前或实验疗法的治疗功效的方法和组合物。

10. 发明申请

WO2004062619A2 SOLUBLE FcγR FUSION PROTEINS AND METHODS OF USE THEREOF 审中-公开
标题翻译：可溶性FcγAM融合蛋白及其使用方法
公开(公告)号：WO2004062619A2
公开(公告)日：2004-07-29
申请号：PCT/US2004/000725
申请日：2004-01-13
申请人： MACROGENICS, INC. , JOHNSON, Leslie, S. , LI, Hua , TUAILLON, Nadine
发明人： JOHNSON, Leslie, S. , LI, Hua , TUAILLON, Nadine
IPC分类号： A61K
CPC分类号： C07K16/283 , A61K39/39541 , A61K2039/505 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2319/30 , C07K2319/32 , A61K2300/00
摘要： The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.
摘要翻译：本发明涉及分子，优选可溶性（即不是膜结合的）多肽，最优选包含FcγR的细胞外可溶性区域的可溶性融合多肽，其衍生物和类似物，以及编码它们的核酸。本发明的分子特别可用于治疗，治疗或预防或改善自身免疫疾病的一种或多种症状，特别是用于改善与免疫性血小板减少性紫癜相关的血小板缺乏症。本发明提供了通过施用本发明的分子来增强用于自身免疫疾病的标准，当前或实验疗法的治疗功效的方法和组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式